18 / 40
Evolución de la supervivencia global en CCRm
¿Qué ha aportado panitumumab?
1.N Eng J Med 2013;369:1023-34; 2. Ann Oncol
2017;28:1862-8.
3.Eur J Cancer 2013;49:S18; 4.
Eur J
Cancer 2015;51:1231–42. 5. Int J Colorectal Dis. 2017;32:1179-90; 6.
J Clin Oncol 2014; 32:5s
(suppl):abstract 3629 (and poster)
; 7. Eur J Cancer 2017; 81:191–202 8;
Informal comparison as these are not head-to-head clinical trials
FOLFOX6 + panitumumab (WT-RAS and left-sided tumour) (n=53)
36.9
28.3
Douillard
1
, 2013
FOLFOX+ panitumumab (WT-RAS WT-BRAF) (n=228)
Peeters
3
, 2013
FOLFOX + panitumumab (WT-RAS receiving anti-VEGF after progression) (n=55)
40.0
26.0
Douillard
1
, 2013
FOLFOX + panitumumab (WT-RAS) (n=259)
30.3
Boeckx
2
, 2017
FOLFOX+ panitumumab (WT-RAS left-sided tumour) (n=168)
Carrato
7
, 2017
FOLFIRI + panitumumab (WT-RAS and LLD) (n=26)
39.0
43.4
0
5
10
15
20
25
Overall survival (months)
30
35
40
FOLFOX + panitumumab (WT-RAS and LLD) (n=48)
40.7
FOLFOX + panitumumab (WT-RAS and WT-BRAF left-sided tumour) (n=156)
32.5
Boeckx
2
, 2017
Douillard
4
2015
FOLFOX6 + panitumumab (WT-RAS WT-BRAF) (n=48)
Carrato
7
, 2017
FOLFOX4 + panitumumab (WT-RAS and LLD) (n=27)
FOLFOX6 + panitumumab (WT-RAS) (n=57)
43.4
41.3
FOLFOX6 + panitumumab (WT-RAS WT-BRAF and left-sided tumour) (n=52)
49.0
PEAK-Ph2:Pmab+FOLFOX vs Bmab+FOLFOX
PRIME-Ph3: Pmab +FOLFOX vs FOLFOX
PLANET-Ph2: Pmab+FOLFOX vs Pmab+FOLFIRI
Boeckx
2
, 2017
Boeckx
2
, 2017
Rivera
5
, 2017
Rivera
5
, 2017
FOLFOX6 + panitumumab (WT-RAS receiving anti-VEGF after progression) (n=35)
Rivera
6
, 2014
41.3
FOLFIRI/FOLFOX4 + panitumumab (WT-RAS and LLD and resected patients) (n=28)
52.0
Carrato
7
, 2017
RAS WT:
CITORREDUCCIÓN
LOCALIZACION IZQUIERDA DEL TUMOR PRIMARIO
SECUENCIA DE TRATAMIENTO